Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review

Anticancer Res. 2016 Nov;36(11):6151-6154. doi: 10.21873/anticanres.11206.

Abstract

Background: Imatinib is generally well tolerated in the treatment of advanced gastrointestinal stromal tumors (GIST). Gastrointestinal vascular ectasia (GIVE) and gastric antral vascular ectasia (GAVE), while rare, are significant under-reported complications of imatinib therapy.

Case report: We present one patient with GIVE complicating imatinib therapy with a literature review of this rare side-effect.

Results: A 68-year-old woman was diagnosed with advanced GIST, wild-type CKIT. After 3 months of treatment with imatinib, she had partial response. However, she was diagnosed with GAVE and, later, also with GIVE. During her 3-year imatinib treatment, she suffered from severe anemia and required blood transfusions. Conservative treatments were not helpful and the ectatic lesions resolved only with cessation of imatinib.

Conclusion: This confirms a causal relationship between GIVE and imatinib. GIVE and GAVE should be considered possible causes of anemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.

Keywords: Gastric antral vascular ectasia; gastrointestinal hemorrhage; gastrointestinal stromal tumors; gastrointestinal vascular ectasia; imatinib.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Female
  • Gastric Antral Vascular Ectasia / chemically induced*
  • Gastric Antral Vascular Ectasia / diagnostic imaging
  • Gastric Antral Vascular Ectasia / therapy
  • Gastrointestinal Stromal Tumors / diagnostic imaging
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Humans
  • Imatinib Mesylate / adverse effects*
  • Multimodal Imaging
  • Positron-Emission Tomography
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Imatinib Mesylate